Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L J W Bosch

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Virchows Archiv : an International Journal of Pathology|June 3, 2017
Early detection: the impact of genomicsM C J van Lanschot, L J W Bosch, M de Wit, et al.
Virchows Archiv : an International Journal of Pathology|July 25, 2012
Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer : future possibilities for personalised treatment by use of biomarkersE M V de Cuba, R Kwakman, M van Egmond, et al.
ESMO Open|June 12, 2025
The role of whole-genome sequencing for guiding systemic therapy in patients with soft tissue sarcomaP van der Laan, W J van Houdt, H van Boven, et al.
ESMO Open|December 4, 2022
Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnosticsL J Schipper, K G Samsom, P Snaebjornsson, et al.
International Journal of Cancer|September 17, 2015
Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancersE M V de Cuba, P Snaebjornsson, D A M Heideman, et al.
Lung Cancer (Amsterdam, Netherlands)|November 18, 2024
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohortJ W T van der Wel, M Jebbink, D van den Broek, et al.
The American Journal of Gastroenterology|November 26, 2019
Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening PopulationL J W Bosch, V Melotte, S Mongera, et al.
BMC Cancer|August 22, 2020
Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort studyS J Schraa, K L van Rooijen, D E W van der Kruijssen, et al.
Lung Cancer (Amsterdam, Netherlands)|October 3, 2025
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS studyJ W T van der Wel, S M Ernst, M Jebbink, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Virchows Archiv : an International Journal of Pathology|June 3, 2017
Early detection: the impact of genomicsM C J van Lanschot, L J W Bosch, M de Wit, et al.
Virchows Archiv : an International Journal of Pathology|July 25, 2012
Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer : future possibilities for personalised treatment by use of biomarkersE M V de Cuba, R Kwakman, M van Egmond, et al.
ESMO Open|June 12, 2025
The role of whole-genome sequencing for guiding systemic therapy in patients with soft tissue sarcomaP van der Laan, W J van Houdt, H van Boven, et al.
ESMO Open|December 4, 2022
Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnosticsL J Schipper, K G Samsom, P Snaebjornsson, et al.
International Journal of Cancer|September 17, 2015
Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancersE M V de Cuba, P Snaebjornsson, D A M Heideman, et al.
Lung Cancer (Amsterdam, Netherlands)|November 18, 2024
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohortJ W T van der Wel, M Jebbink, D van den Broek, et al.
The American Journal of Gastroenterology|November 26, 2019
Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening PopulationL J W Bosch, V Melotte, S Mongera, et al.
BMC Cancer|August 22, 2020
Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort studyS J Schraa, K L van Rooijen, D E W van der Kruijssen, et al.
Lung Cancer (Amsterdam, Netherlands)|October 3, 2025
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS studyJ W T van der Wel, S M Ernst, M Jebbink, et al.
Pageof 1